Aardvark Therapeutics (AARD) Preferred Stock Liabilities (2024)
Aardvark Therapeutics (AARD) reported Preferred Stock Liabilities of $126.8 million for Q4 2024, little changed sequentially from $126.8 million in Q3 2024.
Aardvark Therapeutics (AARD) Preferred Stock Liabilities (2024) Analysis & Trends
Aardvark Therapeutics (AARD) has 1 years of Preferred Stock Liabilities data on file, last reported at $126.8 million in Q4 2024.
- For the quarter ending Q4 2024, Preferred Stock Liabilities changed N/A year-over-year to $126.8 million; the trailing twelve-month figure through Dec 2024 stood at $126.8 million (changed N/A YoY), and the FY2024 full-year result was $126.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $126.8 million in Q4 2024, from $126.8 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $126.8 million in Q2 2024 to a low of $43.9 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Aardvark Therapeutics | 139.40 Mn | 19.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 126.76 Mn |
| Sep 30, 2024 | 126.76 Mn |
| Jun 30, 2024 | 126.85 Mn |
| Mar 31, 2024 | 43.90 Mn |